{
    "info": {
        "nct_id": "NCT04947319",
        "official_title": "An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)",
        "inclusion_criteria": "Inclusion Criteria (Part A)\n\n1. Written informed consent by the patient prior to screening\n2. Patients aged ≥ 18 years on the day of consenting to the study\n3. Pathologic diagnosis of PCNSL\n4. Relapse or refractory PCNSL with at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL\n5. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced magnetic resonance imaging (MRI) performed within 14 days before starting tirabrutinib treatment\n6. Eastern Cooperative Oncology Group performance score (ECOG PS) of 0, 1 or 2\n7. Life expectancy of at least 3 months\n8. Adequate bone marrow, renal, and hepatic function\n\nInclusion Criteria (Part B)\n\n1. Written informed consent by the patient prior to screening\n2. Patients aged ≥ 18 years on the day of consenting to the study\n3. Pathologic diagnosis of PCNSL within the past 3 months\n4. No prior anti-tumor treatments for PCNSL\n5. Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen\n6. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced MRI performed within 14 days before starting study treatment\n7. ECOG PS of 0, 1 or 2\n8. Life expectancy of at least 6 months\n9. Adequate bone marrow, renal, and hepatic function\n\nExclusion Criteria (Part A)\n\n1. Intraocular PCNSL with no brain lesion\n2. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents\n3. Patient with non-B cell PCNSL\n4. Patient with systemic presence of lymphoma\n5. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment\n6. Prior BTK inhibitor treatment\n7. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment\n8. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:\n\n   * Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL\n   * Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both\n9. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment\n10. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment\n11. Active malignancy, other than PCNSL requiring systemic therapy\n12. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments\n13. Patient with bleeding diathesis\n14. Patients with a history of moderate or severe hepatic impairment\n15. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval\n16. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic\n17. Prior history of hypersensitivity or anaphylaxis to tirabrutinib\n18. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis\n19. Medical history of organ allografts\n20. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, hepatitis B (HB) antigen, or hepatitis C virus (HCV) antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.\n21. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.\n22. Women who are pregnant or lactating\n23. Patient is found incapable of giving consent due to dementia or another such condition\n24. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.\n\nExclusion Criteria (Part B)\n\n1. Intraocular PCNSL with no brain lesion\n2. Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are contraindicated\n3. Patients with a history of intolerable toxicity, hypersensitivity, anaphylaxis to the selected backbone regimen medications\n4. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents\n5. Patient with non-B cell PCNSL\n6. Patient with systemic presence of lymphoma\n7. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment\n8. Prior BTK inhibitor treatment\n9. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment\n10. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:\n\n    * Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL\n    * Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both\n11. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment\n12. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment\n13. Active malignancy, other than PCNSL requiring systemic therapy\n14. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments\n15. Patient with bleeding diathesis\n16. Patients with a history of moderate or severe hepatic impairment\n17. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval\n18. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic\n19. Prior history of hypersensitivity or anaphylaxis to tirabrutinib\n20. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis\n21. Medical history of organ allografts\n22. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, HBs antigen, or HCV antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.\n23. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.\n24. Women who are pregnant or lactating\n25. Patient is found incapable of giving consent due to dementia or another such condition\n26. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "13. Patient with bleeding diathesis",
                "criterions": [
                    {
                        "exact_snippets": "Patient with bleeding diathesis",
                        "criterion": "bleeding diathesis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient with bleeding diathesis",
                        "criterion": "bleeding diathesis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "24. Women who are pregnant or lactating",
                "criterions": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "ongoing basis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "time window before starting tirabrutinib",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "ongoing basis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "time window before starting tirabrutinib",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Active malignancy, other than PCNSL requiring systemic therapy",
                "criterions": [
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are contraindicated",
                "criterions": [
                    {
                        "exact_snippets": "Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are contraindicated",
                        "criterion": "contraindication to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are contraindicated",
                        "criterion": "contraindication to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                        "criterion": "prior investigational drug use",
                        "requirement": {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                        "criterion": "prior investigational drug use",
                        "requirement": {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Active malignancy, other than PCNSL requiring systemic therapy",
                "criterions": [
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                        "criterion": "active malignancy (other than PCNSL)",
                        "requirement": {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced magnetic resonance imaging (MRI) performed within 14 days before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in gadolinium enhanced magnetic resonance imaging (MRI)",
                        "criterion": "imaging modality",
                        "requirement": {
                            "requirement_type": "modality",
                            "expected_value": "gadolinium enhanced MRI"
                        }
                    },
                    {
                        "exact_snippets": "performed within 14 days before starting tirabrutinib treatment",
                        "criterion": "MRI timing",
                        "requirement": {
                            "requirement_type": "time before treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in gadolinium enhanced magnetic resonance imaging (MRI)",
                        "criterion": "imaging modality",
                        "requirement": {
                            "requirement_type": "modality",
                            "expected_value": "gadolinium enhanced MRI"
                        }
                    },
                    {
                        "exact_snippets": "performed within 14 days before starting tirabrutinib treatment",
                        "criterion": "MRI timing",
                        "requirement": {
                            "requirement_type": "time before treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments",
                "criterions": [
                    {
                        "exact_snippets": "Poorly controlled comorbidity",
                        "criterion": "comorbidity",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    },
                    {
                        "exact_snippets": "severe heart",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "severe lung disease",
                        "criterion": "lung disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant liver diseases",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Poorly controlled comorbidity",
                        "criterion": "comorbidity",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    },
                    {
                        "exact_snippets": "severe heart",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "severe lung disease",
                        "criterion": "lung disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant liver diseases",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "21. Medical history of organ allografts",
                "criterions": [
                    {
                        "exact_snippets": "Medical history of organ allografts",
                        "criterion": "organ allograft",
                        "requirement": {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Medical history of organ allografts",
                        "criterion": "organ allograft",
                        "requirement": {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "20. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis",
                "criterions": [
                    {
                        "exact_snippets": "Prior history of Stevens Johnson Syndrome",
                        "criterion": "Stevens Johnson Syndrome",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of ... Toxic Epidermal Necrolysis",
                        "criterion": "Toxic Epidermal Necrolysis",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior history of Stevens Johnson Syndrome",
                        "criterion": "Stevens Johnson Syndrome",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of ... Toxic Epidermal Necrolysis",
                        "criterion": "Toxic Epidermal Necrolysis",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                "criterions": [
                    {
                        "exact_snippets": "Prior history of hypersensitivity ... to tirabrutinib",
                        "criterion": "hypersensitivity to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of ... anaphylaxis to tirabrutinib",
                        "criterion": "anaphylaxis to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior history of hypersensitivity ... to tirabrutinib",
                        "criterion": "hypersensitivity to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of ... anaphylaxis to tirabrutinib",
                        "criterion": "anaphylaxis to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Life expectancy of at least 6 months",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy of at least 6 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy of at least 6 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "24. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                        "criterion": "investigator-determined eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                        "criterion": "investigator-determined eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen",
                "criterions": [
                    {
                        "exact_snippets": "Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen",
                        "criterion": "suitability for high dose methotrexate containing regimen",
                        "requirement": {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen",
                        "criterion": "suitability for high dose methotrexate containing regimen",
                        "requirement": {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen",
                        "criterion": "suitability for high dose methotrexate containing regimen",
                        "requirement": {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen",
                        "criterion": "suitability for high dose methotrexate containing regimen",
                        "requirement": {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced MRI performed within 14 days before starting study treatment",
                "criterions": [
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "gadolinium enhanced MRI performed within 14 days before starting study treatment",
                        "criterion": "gadolinium enhanced MRI",
                        "requirement": {
                            "requirement_type": "performance time",
                            "expected_value": "within 14 days before starting study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "gadolinium enhanced MRI performed within 14 days before starting study treatment",
                        "criterion": "gadolinium enhanced MRI",
                        "requirement": {
                            "requirement_type": "performance time",
                            "expected_value": "within 14 days before starting study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "23. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.",
                "criterions": [
                    {
                        "exact_snippets": "unable to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "has malabsorption, malabsorption syndrome",
                        "criterion": "malabsorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "comorbidity that affects gastric function",
                        "criterion": "comorbidity affecting gastric function",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "undergone complete resection of the stomach or small intestine",
                        "criterion": "complete resection of the stomach or small intestine",
                        "requirement": {
                            "requirement_type": "history of surgery",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "has ulcerative colitis",
                        "criterion": "ulcerative colitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic inflammatory bowel disease",
                        "criterion": "symptomatic inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "partial or complete intestinal obstruction",
                        "criterion": "intestinal obstruction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "unable to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "has malabsorption, malabsorption syndrome",
                        "criterion": "malabsorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "comorbidity that affects gastric function",
                        "criterion": "comorbidity affecting gastric function",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "undergone complete resection of the stomach or small intestine",
                        "criterion": "complete resection of the stomach or small intestine",
                        "requirement": {
                            "requirement_type": "history of surgery",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "has ulcerative colitis",
                        "criterion": "ulcerative colitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic inflammatory bowel disease",
                        "criterion": "symptomatic inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "partial or complete intestinal obstruction",
                        "criterion": "intestinal obstruction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "Prior chemotherapy within 21 days",
                        "criterion": "prior chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "nitrosourea within 42 days",
                        "criterion": "prior nitrosourea treatment",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "an antibody drug with anticancer activity (e.g., rituximab) within 28 days",
                        "criterion": "prior antibody drug with anticancer activity",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior radiotherapy within 14 days",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior major invasive surgery within 28 days",
                        "criterion": "prior major invasive surgery",
                        "requirement": {
                            "requirement_type": "time since last surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "allogeneic stem cell transplant within 6 months",
                        "criterion": "prior allogeneic stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since last transplant",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior chemotherapy within 21 days",
                        "criterion": "prior chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "nitrosourea within 42 days",
                        "criterion": "prior nitrosourea treatment",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "an antibody drug with anticancer activity (e.g., rituximab) within 28 days",
                        "criterion": "prior antibody drug with anticancer activity",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior radiotherapy within 14 days",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior major invasive surgery within 28 days",
                        "criterion": "prior major invasive surgery",
                        "requirement": {
                            "requirement_type": "time since last surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "allogeneic stem cell transplant within 6 months",
                        "criterion": "prior allogeneic stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since last transplant",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "22. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, HBs antigen, or HCV antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.",
                "criterions": [
                    {
                        "exact_snippets": "Tests positive for HIV-1 antibody",
                        "criterion": "HIV-1 antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... HIV-2 antibody",
                        "criterion": "HIV-2 antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... human T-lymphotropic virus 1 antibody",
                        "criterion": "human T-lymphotropic virus 1 antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... HBs antigen",
                        "criterion": "HBs antigen",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... HCV antibody",
                        "criterion": "HCV antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for HBs antibody ... and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                        "criterion": "HBs antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... hepatitis B virus core protein antibody ... and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                        "criterion": "hepatitis B virus core protein antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                        "criterion": "hepatitis B virus deoxyribonucleic acid (HBV DNA)",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "detectable"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Tests positive for HIV-1 antibody",
                                "criterion": "HIV-1 antibody",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "positive"
                                }
                            },
                            {
                                "exact_snippets": "Tests positive for ... HIV-2 antibody",
                                "criterion": "HIV-2 antibody",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "positive"
                                }
                            },
                            {
                                "exact_snippets": "Tests positive for ... human T-lymphotropic virus 1 antibody",
                                "criterion": "human T-lymphotropic virus 1 antibody",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "positive"
                                }
                            },
                            {
                                "exact_snippets": "Tests positive for ... HBs antigen",
                                "criterion": "HBs antigen",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "positive"
                                }
                            },
                            {
                                "exact_snippets": "Tests positive for ... HCV antibody",
                                "criterion": "HCV antibody",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "positive"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Tests positive for HBs antibody ... and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                                        "criterion": "HBs antibody",
                                        "requirement": {
                                            "requirement_type": "test result",
                                            "expected_value": "positive"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Tests positive for ... hepatitis B virus core protein antibody ... and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                                        "criterion": "hepatitis B virus core protein antibody",
                                        "requirement": {
                                            "requirement_type": "test result",
                                            "expected_value": "positive"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                                "criterion": "hepatitis B virus deoxyribonucleic acid (HBV DNA)",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "detectable"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Written informed consent by the patient prior to screening",
                "criterions": [
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "written"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provider",
                            "expected_value": "patient"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "written"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provider",
                            "expected_value": "patient"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "ongoing basis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "ongoing basis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Patient with systemic presence of lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "systemic presence of lymphoma",
                        "criterion": "lymphoma",
                        "requirement": {
                            "requirement_type": "systemic presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "systemic presence of lymphoma",
                        "criterion": "lymphoma",
                        "requirement": {
                            "requirement_type": "systemic presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                "criterions": [
                    {
                        "exact_snippets": "QTcF > 480 milliseconds",
                        "criterion": "QTcF interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "milliseconds"
                            }
                        }
                    },
                    {
                        "exact_snippets": "requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                        "criterion": "concomitant medications that prolong the QT interval",
                        "requirement": {
                            "requirement_type": "ongoing treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "QTcF > 480 milliseconds",
                        "criterion": "QTcF interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "milliseconds"
                            }
                        }
                    },
                    {
                        "exact_snippets": "requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                        "criterion": "concomitant medications that prolong the QT interval",
                        "requirement": {
                            "requirement_type": "ongoing treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Pathologic diagnosis of PCNSL",
                "criterions": [
                    {
                        "exact_snippets": "Pathologic diagnosis of PCNSL",
                        "criterion": "PCNSL (primary central nervous system lymphoma)",
                        "requirement": {
                            "requirement_type": "pathologic diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Pathologic diagnosis of PCNSL",
                        "criterion": "PCNSL (primary central nervous system lymphoma)",
                        "requirement": {
                            "requirement_type": "pathologic diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "25. Patient is found incapable of giving consent due to dementia or another such condition",
                "criterions": [
                    {
                        "exact_snippets": "incapable of giving consent due to dementia or another such condition",
                        "criterion": "capacity to give consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "dementia or another such condition",
                        "criterion": "dementia or similar condition",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "incapable of giving consent due to dementia or another such condition",
                                "criterion": "capacity to give consent",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "dementia or another such condition",
                                "criterion": "dementia or similar condition",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Patient with bleeding diathesis",
                "criterions": [
                    {
                        "exact_snippets": "Patient with bleeding diathesis",
                        "criterion": "bleeding diathesis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient with bleeding diathesis",
                        "criterion": "bleeding diathesis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Intraocular PCNSL with no brain lesion",
                "criterions": [
                    {
                        "exact_snippets": "Intraocular PCNSL",
                        "criterion": "intraocular primary central nervous system lymphoma (PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no brain lesion",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Intraocular PCNSL",
                        "criterion": "intraocular primary central nervous system lymphoma (PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no brain lesion",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. No prior anti-tumor treatments for PCNSL",
                "criterions": [
                    {
                        "exact_snippets": "No prior anti-tumor treatments for PCNSL",
                        "criterion": "prior anti-tumor treatments for PCNSL",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No prior anti-tumor treatments for PCNSL",
                        "criterion": "prior anti-tumor treatments for PCNSL",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria (Part A)",
                "criterions": [
                    {
                        "exact_snippets": "Inclusion Criteria (Part A)",
                        "criterion": "inclusion criteria for Part A",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Inclusion Criteria (Part A)",
                        "criterion": "inclusion criteria for Part A",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Life expectancy of at least 3 months",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy of at least 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy of at least 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria (Part B)",
                "criterions": [
                    {
                        "exact_snippets": "Exclusion Criteria (Part B)",
                        "criterion": "exclusion criteria for Part B",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Exclusion Criteria (Part B)",
                        "criterion": "exclusion criteria for Part B",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Pathologic diagnosis of PCNSL within the past 3 months",
                "criterions": [
                    {
                        "exact_snippets": "Pathologic diagnosis of PCNSL",
                        "criterion": "pathologic diagnosis of PCNSL",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "within the past 3 months",
                        "criterion": "time since pathologic diagnosis of PCNSL",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Pathologic diagnosis of PCNSL",
                        "criterion": "pathologic diagnosis of PCNSL",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "within the past 3 months",
                        "criterion": "time since pathologic diagnosis of PCNSL",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Written informed consent by the patient prior to screening",
                "criterions": [
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": "written"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provider",
                            "expected_value": "patient"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": "written"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    },
                    {
                        "exact_snippets": "Written informed consent by the patient prior to screening",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provider",
                            "expected_value": "patient"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis",
                "criterions": [
                    {
                        "exact_snippets": "Prior history of Stevens Johnson Syndrome",
                        "criterion": "Stevens Johnson Syndrome",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of ... Toxic Epidermal Necrolysis",
                        "criterion": "Toxic Epidermal Necrolysis",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior history of Stevens Johnson Syndrome",
                        "criterion": "Stevens Johnson Syndrome",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of ... Toxic Epidermal Necrolysis",
                        "criterion": "Toxic Epidermal Necrolysis",
                        "requirement": {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "20. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, hepatitis B (HB) antigen, or hepatitis C virus (HCV) antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.",
                "criterions": [
                    {
                        "exact_snippets": "Tests positive for HIV-1 antibody",
                        "criterion": "HIV-1 antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... HIV-2 antibody",
                        "criterion": "HIV-2 antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... human T-lymphotropic virus 1 antibody",
                        "criterion": "human T-lymphotropic virus 1 antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... hepatitis B (HB) antigen",
                        "criterion": "hepatitis B antigen",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for ... hepatitis C virus (HCV) antibody",
                        "criterion": "hepatitis C virus antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                        "criterion": "HBs antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                        "criterion": "hepatitis B virus core protein antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                        "criterion": "hepatitis B virus deoxyribonucleic acid assay",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "detectable"
                            }
                        }
                    },
                    {
                        "exact_snippets": "despite testing negative for HBs antigen",
                        "criterion": "HBs antigen",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "or_criteria": [
                                            {
                                                "or_criteria": [
                                                    {
                                                        "exact_snippets": "Tests positive for HIV-1 antibody",
                                                        "criterion": "HIV-1 antibody",
                                                        "requirement": {
                                                            "requirement_type": "test result",
                                                            "expected_value": "positive"
                                                        }
                                                    },
                                                    {
                                                        "exact_snippets": "Tests positive for ... HIV-2 antibody",
                                                        "criterion": "HIV-2 antibody",
                                                        "requirement": {
                                                            "requirement_type": "test result",
                                                            "expected_value": "positive"
                                                        }
                                                    }
                                                ]
                                            },
                                            {
                                                "exact_snippets": "Tests positive for ... human T-lymphotropic virus 1 antibody",
                                                "criterion": "human T-lymphotropic virus 1 antibody",
                                                "requirement": {
                                                    "requirement_type": "test result",
                                                    "expected_value": "positive"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "Tests positive for ... hepatitis B (HB) antigen",
                                        "criterion": "hepatitis B antigen",
                                        "requirement": {
                                            "requirement_type": "test result",
                                            "expected_value": "positive"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "Tests positive for ... hepatitis C virus (HCV) antibody",
                                "criterion": "hepatitis C virus antibody",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "positive"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                                        "criterion": "HBs antibody",
                                        "requirement": {
                                            "requirement_type": "test result",
                                            "expected_value": "positive"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                                        "criterion": "hepatitis B virus core protein antibody",
                                        "requirement": {
                                            "requirement_type": "test result",
                                            "expected_value": "positive"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                                "criterion": "hepatitis B virus deoxyribonucleic acid assay",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "detectable"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "despite testing negative for HBs antigen",
                                "criterion": "HBs antigen",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "negative"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "23. Patient is found incapable of giving consent due to dementia or another such condition",
                "criterions": [
                    {
                        "exact_snippets": "incapable of giving consent",
                        "criterion": "capacity to give consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "dementia or another such condition",
                        "criterion": "dementia or similar condition",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "incapable of giving consent",
                        "criterion": "capacity to give consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "dementia or another such condition",
                        "criterion": "dementia or similar condition",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Medical history of organ allografts",
                "criterions": [
                    {
                        "exact_snippets": "Medical history of organ allografts",
                        "criterion": "organ allograft",
                        "requirement": {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Medical history of organ allografts",
                        "criterion": "organ allograft",
                        "requirement": {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Adequate bone marrow, renal, and hepatic function",
                "criterions": [
                    {
                        "exact_snippets": "Adequate bone marrow ... function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal ... function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate bone marrow ... function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal ... function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria (Part A)",
                "criterions": [
                    {
                        "exact_snippets": "Exclusion Criteria (Part A)",
                        "criterion": "exclusion criteria for Part A",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Exclusion Criteria (Part A)",
                        "criterion": "exclusion criteria for Part A",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL",
                "criterions": [
                    {
                        "exact_snippets": "Equivalent of up to 10 mg/day of prednisone",
                        "criterion": "prednisone dosage",
                        "requirement": {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for a disease other than PCNSL",
                        "criterion": "disease indication for prednisone",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "PCNSL"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Equivalent of up to 10 mg/day of prednisone",
                        "criterion": "prednisone dosage",
                        "requirement": {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for a disease other than PCNSL",
                        "criterion": "disease indication for prednisone",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "PCNSL"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Patient with systemic presence of lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "systemic presence of lymphoma",
                        "criterion": "lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "systemic presence of lymphoma",
                        "criterion": "lymphoma",
                        "requirement": {
                            "requirement_type": "systemic",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "systemic presence of lymphoma",
                        "criterion": "lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "systemic presence of lymphoma",
                        "criterion": "lymphoma",
                        "requirement": {
                            "requirement_type": "systemic",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "22. Women who are pregnant or lactating",
                "criterions": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Patient with non-B cell PCNSL",
                "criterions": [
                    {
                        "exact_snippets": "Patient with non-B cell PCNSL",
                        "criterion": "PCNSL subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": "non-B cell"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient with non-B cell PCNSL",
                        "criterion": "PCNSL subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": "non-B cell"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "Prior chemotherapy within 21 days ... before starting tirabrutinib treatment",
                        "criterion": "prior chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "nitrosourea within 42 days ... before starting tirabrutinib treatment",
                        "criterion": "prior nitrosourea treatment",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "an antibody drug with anticancer activity (e.g., rituximab) within 28 days ... before starting tirabrutinib treatment",
                        "criterion": "prior antibody drug with anticancer activity",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior radiotherapy within 14 days ... before starting tirabrutinib treatment",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior major invasive surgery within 28 days ... before starting tirabrutinib treatment",
                        "criterion": "prior major invasive surgery",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment",
                        "criterion": "prior allogeneic stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior chemotherapy within 21 days ... before starting tirabrutinib treatment",
                        "criterion": "prior chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "nitrosourea within 42 days ... before starting tirabrutinib treatment",
                        "criterion": "prior nitrosourea treatment",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "an antibody drug with anticancer activity (e.g., rituximab) within 28 days ... before starting tirabrutinib treatment",
                        "criterion": "prior antibody drug with anticancer activity",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior radiotherapy within 14 days ... before starting tirabrutinib treatment",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior major invasive surgery within 28 days ... before starting tirabrutinib treatment",
                        "criterion": "prior major invasive surgery",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment",
                        "criterion": "prior allogeneic stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments",
                "criterions": [
                    {
                        "exact_snippets": "Poorly controlled comorbidity",
                        "criterion": "comorbidity",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    },
                    {
                        "exact_snippets": "severe heart",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "severe lung disease",
                        "criterion": "lung disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant liver diseases",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Poorly controlled comorbidity",
                        "criterion": "comorbidity",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    },
                    {
                        "exact_snippets": "severe heart",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "severe lung disease",
                        "criterion": "lung disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant liver diseases",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    },
                    {
                        "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin derivative anticoagulant use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin derivative anticoagulant use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    },
                    {
                        "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "vitamin K antagonist use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "vitamin K antagonist use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    },
                    {
                        "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "novel oral anticoagulant use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "novel oral anticoagulant use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    },
                    {
                        "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "antiplatelet therapy use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "antiplatelet therapy use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin derivative anticoagulant use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin derivative anticoagulant use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "vitamin K antagonist use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "vitamin K antagonist use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "novel oral anticoagulant use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "novel oral anticoagulant use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "antiplatelet therapy use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "antiplatelet therapy use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Patients with a history of intolerable toxicity, hypersensitivity, anaphylaxis to the selected backbone regimen medications",
                "criterions": [
                    {
                        "exact_snippets": "history of intolerable toxicity ... to the selected backbone regimen medications",
                        "criterion": "intolerable toxicity to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ... hypersensitivity ... to the selected backbone regimen medications",
                        "criterion": "hypersensitivity to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ... anaphylaxis to the selected backbone regimen medications",
                        "criterion": "anaphylaxis to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "history of intolerable toxicity ... to the selected backbone regimen medications",
                        "criterion": "intolerable toxicity to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ... hypersensitivity ... to the selected backbone regimen medications",
                        "criterion": "hypersensitivity to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ... anaphylaxis to the selected backbone regimen medications",
                        "criterion": "anaphylaxis to backbone regimen medications",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents",
                "criterions": [
                    {
                        "exact_snippets": "intolerant of contrast enhanced MRI",
                        "criterion": "contrast enhanced MRI intolerance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "due to allergic reactions to contrast agents",
                        "criterion": "allergic reactions to contrast agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "intolerant of contrast enhanced MRI",
                        "criterion": "contrast enhanced MRI intolerance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "due to allergic reactions to contrast agents",
                        "criterion": "allergic reactions to contrast agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Prior BTK inhibitor treatment",
                "criterions": [
                    {
                        "exact_snippets": "Prior BTK inhibitor treatment",
                        "criterion": "BTK inhibitor treatment",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior BTK inhibitor treatment",
                        "criterion": "BTK inhibitor treatment",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                        "criterion": "prior investigational drug use",
                        "requirement": {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                        "criterion": "prior investigational drug use",
                        "requirement": {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Prior BTK inhibitor treatment",
                "criterions": [
                    {
                        "exact_snippets": "Prior BTK inhibitor treatment",
                        "criterion": "BTK inhibitor treatment",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior BTK inhibitor treatment",
                        "criterion": "BTK inhibitor treatment",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Adequate bone marrow, renal, and hepatic function",
                "criterions": [
                    {
                        "exact_snippets": "Adequate bone marrow ... function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal ... function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate bone marrow ... function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal ... function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Patient with non-B cell PCNSL",
                "criterions": [
                    {
                        "exact_snippets": "Patient with non-B cell PCNSL",
                        "criterion": "PCNSL subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": "non-B cell"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient with non-B cell PCNSL",
                        "criterion": "PCNSL subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": "non-B cell"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                "criterions": [
                    {
                        "exact_snippets": "QTcF > 480 milliseconds",
                        "criterion": "QTcF interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "milliseconds"
                            }
                        }
                    },
                    {
                        "exact_snippets": "requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                        "criterion": "ongoing treatment with concomitant medications that prolong the QT interval",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "QTcF > 480 milliseconds",
                        "criterion": "QTcF interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "milliseconds"
                            }
                        }
                    },
                    {
                        "exact_snippets": "requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                        "criterion": "ongoing treatment with concomitant medications that prolong the QT interval",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL",
                "criterions": [
                    {
                        "exact_snippets": "Equivalent of up to 10 mg/day of prednisone",
                        "criterion": "prednisone dosage",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for a disease other than PCNSL",
                        "criterion": "disease indication for prednisone",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "PCNSL"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Equivalent of up to 10 mg/day of prednisone",
                        "criterion": "prednisone dosage",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for a disease other than PCNSL",
                        "criterion": "disease indication for prednisone",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "PCNSL"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents",
                "criterions": [
                    {
                        "exact_snippets": "intolerant of contrast enhanced MRI",
                        "criterion": "contrast enhanced MRI intolerance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "due to allergic reactions to contrast agents",
                        "criterion": "allergic reactions to contrast agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "condition": {
                            "exact_snippets": "intolerant of contrast enhanced MRI",
                            "criterion": "contrast enhanced MRI intolerance",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        },
                        "then_criteria": {
                            "exact_snippets": "due to allergic reactions to contrast agents",
                            "criterion": "allergic reactions to contrast agents",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                "criterions": [
                    {
                        "exact_snippets": "Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                        "criterion": "hypersensitivity to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                        "criterion": "anaphylaxis to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                        "criterion": "hypersensitivity to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                        "criterion": "anaphylaxis to tirabrutinib",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin derivative anticoagulant use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "warfarin derivative anticoagulant use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "vitamin K antagonist use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "vitamin K antagonist use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "novel oral anticoagulant use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "novel oral anticoagulant use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "antiplatelet therapy use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                        "criterion": "antiplatelet therapy use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib treatment"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin derivative anticoagulant use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "warfarin derivative anticoagulant use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib treatment"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "vitamin K antagonist use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "vitamin K antagonist use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib treatment"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "novel oral anticoagulant use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "novel oral anticoagulant use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib treatment"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "antiplatelet therapy use",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                                "criterion": "antiplatelet therapy use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before starting tirabrutinib treatment"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria (Part B)",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "11. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "received a CYP3A4 inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "CYP3A4 inducer administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "received a ... P-gp inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "P-gp inducer administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "received a CYP3A4 inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "CYP3A4 inducer administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "received a ... P-gp inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "P-gp inducer administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Intraocular PCNSL with no brain lesion",
                "criterions": [
                    {
                        "exact_snippets": "Intraocular PCNSL",
                        "criterion": "intraocular primary central nervous system lymphoma (PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no brain lesion",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Intraocular PCNSL",
                        "criterion": "intraocular primary central nervous system lymphoma (PCNSL)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no brain lesion",
                        "criterion": "brain lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment",
                "criterions": [
                    {
                        "exact_snippets": "received a CYP3A4 inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "CYP3A4 inducer administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "received a ... P-gp inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "P-gp inducer administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "received a CYP3A4 inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "CYP3A4 inducer administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "received a ... P-gp inducer within 14 days before starting tirabrutinib treatment",
                        "criterion": "P-gp inducer administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "21. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.",
                "criterions": [
                    {
                        "exact_snippets": "unable to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "has malabsorption, malabsorption syndrome",
                        "criterion": "malabsorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "comorbidity that affects gastric function",
                        "criterion": "comorbidity affecting gastric function",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "undergone complete resection of the stomach or small intestine",
                        "criterion": "complete resection of the stomach or small intestine",
                        "requirement": {
                            "requirement_type": "history of surgery",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "has ulcerative colitis",
                        "criterion": "ulcerative colitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic inflammatory bowel disease",
                        "criterion": "symptomatic inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "partial or complete intestinal obstruction",
                        "criterion": "intestinal obstruction",
                        "requirement": {
                            "requirement_type": "degree",
                            "expected_value": [
                                "partial",
                                "complete"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Relapse or refractory PCNSL with at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL",
                "criterions": [
                    {
                        "exact_snippets": "Relapse or refractory PCNSL",
                        "criterion": "PCNSL disease status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapse",
                                "refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL",
                        "criterion": "prior HD-MTX based therapy for PCNSL",
                        "requirement": {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both",
                "criterions": [
                    {
                        "exact_snippets": "Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone)",
                        "criterion": "corticosteroid dosage",
                        "requirement": {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "mg/day prednisone equivalent"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone)",
                        "criterion": "corticosteroid dosage",
                        "requirement": {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "mg/day dexamethasone equivalent"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for patients with lesions of the brain or spinal cord or both",
                        "criterion": "lesions location",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": [
                                "brain",
                                "spinal cord"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "26. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                        "criterion": "investigator-determined eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                        "criterion": "investigator-determined eligibility",
                        "requirement": {
                            "requirement_type": "determined_by",
                            "expected_value": [
                                "Investigator",
                                "sub-Investigator"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Patients aged ≥ 18 years on the day of consenting to the study",
                "criterions": [
                    {
                        "exact_snippets": "Patients aged ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients aged \u0000\u0000e2\u000089\u0000a5 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                "criterions": [
                    {
                        "exact_snippets": "Active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including a HIV, cytomegalovirus infection or SARS-CoV-2",
                        "criterion": "specific active infections",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": [
                                "HIV",
                                "cytomegalovirus infection",
                                "SARS-CoV-2"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                        "criterion": "recent serious infection",
                        "requirement": {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                        "criterion": "recent serious infection",
                        "requirement": {
                            "requirement_type": "treatment required",
                            "expected_value": [
                                "hospitalization",
                                "intravenous antibiotic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                        "criterion": "recent serious infection",
                        "requirement": {
                            "requirement_type": "infection type exclusion",
                            "expected_value": "not nail trichophytosis"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "16. Patients with a history of moderate or severe hepatic impairment",
                "criterions": [
                    {
                        "exact_snippets": "history of moderate or severe hepatic impairment",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of moderate or severe hepatic impairment",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "14. Patients with a history of moderate or severe hepatic impairment",
                "criterions": [
                    {
                        "exact_snippets": "history of moderate or severe hepatic impairment",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of moderate or severe hepatic impairment",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Patients aged ≥ 18 years on the day of consenting to the study",
                "criterions": [
                    {
                        "exact_snippets": "Patients aged ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients aged \u0013e 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Eastern Cooperative Oncology Group performance score (ECOG PS) of 0, 1 or 2",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group performance score (ECOG PS) of 0, 1 or 2",
                        "criterion": "Eastern Cooperative Oncology Group performance score (ECOG PS)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both",
                "criterions": [
                    {
                        "exact_snippets": "Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone)",
                        "criterion": "corticosteroid dosage",
                        "requirement": {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "mg/day prednisone"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone)",
                        "criterion": "corticosteroid dosage",
                        "requirement": {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "mg/day dexamethasone"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for patients with lesions of the brain or spinal cord or both",
                        "criterion": "lesions location",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": [
                                "brain",
                                "spinal cord"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "16. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                "criterions": [
                    {
                        "exact_snippets": "Active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including a HIV, cytomegalovirus infection or SARS-CoV-2",
                        "criterion": "specific infections (HIV, cytomegalovirus, SARS-CoV-2)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                        "criterion": "recent serious infection (excluding nail trichophytosis)",
                        "requirement": {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                        "criterion": "recent serious infection (excluding nail trichophytosis)",
                        "requirement": {
                            "requirement_type": "treatment required",
                            "expected_value": [
                                "hospitalization",
                                "intravenous antibiotic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                        "criterion": "recent serious infection (excluding nail trichophytosis)",
                        "requirement": {
                            "requirement_type": "infection type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "nail trichophytosis"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "7. ECOG PS of 0, 1 or 2",
                "criterions": [
                    {
                        "exact_snippets": "ECOG PS of 0, 1 or 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}